What's Happening?
ADC Therapeutics has announced promising results from its Phase 3 LOTIS-5 trial, evaluating ZYNLONTA in combination with rituximab for relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). The trial demonstrated statistical significance in progression-free
survival and showed no detrimental effect on overall survival. The combination therapy achieved higher complete response rates and longer durations of response compared to the control arm. Despite similar rates of treatment emergent adverse events between the arms, serious adverse events were more prevalent in the test arm, particularly among older patients. ADC Therapeutics plans to discuss the benefit-risk profile with the U.S. FDA and prepare for a supplemental Biologics License Application.
Why It's Important?
The LOTIS-5 trial results are crucial for advancing treatment options for patients with r/r DLBCL, a challenging form of lymphoma. The combination of ZYNLONTA and rituximab offers a potential new therapeutic strategy, especially for patients who have exhausted other treatment avenues. The positive outcomes could lead to regulatory approval, expanding the availability of effective treatments and improving patient prognosis. This development highlights the importance of innovative drug combinations in oncology and the potential for improving survival rates in aggressive cancers.
What's Next?
ADC Therapeutics intends to conduct a pre-sBLA meeting with the FDA in August and aims to submit a planned sBLA in the fourth quarter of 2026. The company will continue evaluating ZYNLONTA in combination studies for other B-cell malignancies and earlier lines of therapy. ADC Therapeutics is also exploring cost reduction initiatives and other strategic options to maximize value and sustain growth.
